The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

Program Overview

This CE activity was designed to improve learners’ knowledge and competence in relation to the management of patients with NT1.

Credit Expired
0.75 CE Credit(s)
Expires: December 1, 2022

Target Audience

This activity is intended for neurology and primary care clinicians involved in the treatment of narcolepsy type 1 (NT1).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize contemporary challenges in the management of narcolepsy type 1 (NT1)
  • Evaluate the role of orexin in the underlying pathophysiology of NT1
  • Analyze available data on emerging orexin-based therapies for the treatment of NT1
  • Identify patients with NT1 who might derive benefit from treatment with orexin-based therapy

Activity Faculty

Thorpy 300x400

Michael J. Thorpy, MD

Professor, Neurology
Albert Einstein College of Medicine
Bronx, New York, United States

Dauvilliers 300x400

Yves Dauvilliers, MD, PhD

Professor, Neurology and Physiology
Sleep Unit, Gui de Chauliac Hospital
University of Montpellier
Montpellier, France

Scammell 300x400

Thomas E. Scammell, MD

Professor, Neurology
Harvard Medical School
Beth Israel Deaconess Medical Center
Boston Children’s Hospital
Boston, Massachusetts, United States

The Evolving Role of Orexin-Based Therapy in Narcolepsy Type 1 Management

Supporter Statement

Provider Statement

Disclosure of Financial Relationships

Faculty

Planners and Managers

Method of Participation and Request for Credit

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer Statement

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Copyright Statement

© Copyright 2024. All rights reserved. Developed and managed by RMEI Medical Education, LLC. Laurel Office Plaza | 101 Laurel Road, Suite 200 | Voorhees, NJ 08043 | www.RMEI.com | (866) 770-RMEI

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources